期刊文献+

右兰索拉唑缓释胶囊治疗糜烂性食管炎的临床疗效观察 被引量:1

下载PDF
导出
摘要 目的:研究右兰索拉唑缓释胶囊治疗糜烂性食管炎的临床疗效及安全性。方法:将60例诊断明确的糜烂性食管炎患者随机分为观察组及对照组,每组各30例,其中观察组给予右兰索拉唑缓释胶囊60 mg,早餐前1 h口服;对照组给予埃索美拉唑肠溶片40 mg,早餐前1 h口服,疗程8周,疗程结束后及停药后的4周观察两组患者的疗效、不良反应发生率及复发率。结果:观察组的总有效率为96.6%,对照组为83.3%;两组比较差异有统计学意义(P<0.05),观察组的不良反应发生率及复发率分别为13.3%和6.6%,明显低于对照组的33.3%和23.3%,两组比较差异有统计学意义(P<0.05)。结论:右兰索拉唑缓释胶囊治疗糜烂性食管炎的临床效果良好,复发率较低,安全性和耐受性良好。
出处 《天津药学》 2020年第4期40-42,共3页 Tianjin Pharmacy
  • 相关文献

参考文献2

二级参考文献13

  • 1KATZ PO, SCHEIMAN JM, BARKUN AN. Review article: acid-related disease-what are the unmet clinical needs? [ J]. Al- iment Pharmacol Ther, 2006,23 ( Suppl 2) : S9 - S22.Ther, 2009,29(7) :731 -741.
  • 2LEE RD, VAKILY M, MULFORD D,et al. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmaco- dynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor: evidence for dosing flexi- bility [ J ]. Aliment Pharmacol Ther, 2009,29 ( 8 ) : 824 - 833.
  • 3LEE RD, WU J, VAKILY M, MULFORD D. Effect of hepatic impairment on the pharmacokinetics of TAK-390MR ( modified release) [ J ]. Clin Pharmacol Ther, 2008,83 ( Suppl 1 ) : s95.
  • 4SHARMA P, SHAHEEN NJ, PEREZ MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation: re- suits from two randomized controlled studies [ J]. Aliment Phar- macol Ther, 2009,29(7) :731 -741.
  • 5VAKILY M, ZHANG W, WU J, et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual de- layed release technology, dexlansoprazole MR : a combined analy- sis of randomized controlled clinical trials [ J ]. Curr Med Res Opin, 2009,25 (3) :627 - 638.
  • 6DABHOLKAR AH, HAN C, PARIS MM, et al. The 12-month Safety Profile of Dexlansoprazole, a Proton Pump Inhibitor with a Dual Delayed Release Formulation, in Patients with Gastro-oeso- phageal Reflux Disease [ J ]. Aliment Pharmacol Ther, 2011,33 (3) :366 -377.
  • 7FASS R, CHE WD, ZAKKO SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on day- time and nighttime heartburn in patients with non-erosive reflux disease[ J]. Aliment Pharmacol Ther, 2009,29(12) :1261 - 1272.
  • 8RICHTER JE. Gastrooesophageal reflux disease [J]. Best Pract Res Clin Gastroenterol, 2007,21 ( 4 ) : 609 - 631.
  • 9KUKULKA M, EISENBERG C, NUDURAPATI S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release es- omeprazole 40 mg [ J ]. Clin Exp Gastroenterol, 2011,4 : 213 - 220.
  • 10FASS R, JOHNSON DA, ORR WC, et al. The Effect of Dexlan- soprazole MR on Nocturnal Heartburn and GERD-Related Sleep Disturbances inpatients with symptomatic GERD [ J ]. Am J Gas- troenterol, 2011,106 ( 3 ) :421 - 431.

共引文献17

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部